Spinal Modulation is a technology company.
Spinal Modulation has raised $57.0M across 2 funding rounds.
Spinal Modulation has raised $57.0M in total across 2 funding rounds.
Spinal Modulation is a medical technology company based in Menlo Park, CA, specializing in developing implantable neurostimulation devices for chronic intractable pain management. Its flagship product, the Axium™ Neurostimulator System, is an innovative spinal cord stimulation (SCS) device designed to deliver targeted electrical pulses to interrupt pain signals, primarily serving patients suffering from chronic leg pain and other persistent pain conditions. The company addresses a significant unmet need in pain management by offering an alternative to traditional therapies, improving patient quality of life. Spinal Modulation has demonstrated strong growth momentum, evidenced by substantial investments such as a $40 million equity infusion from St. Jude Medical, which also secured exclusive distribution and acquisition options, signaling confidence in the technology and market potential[1][5][6].
Spinal Modulation was founded as a small start-up focused on developing nerve stimulation therapies to disrupt pain transmission. The founding team brought expertise in neuromodulation and implantable medical devices, identifying a gap in effective treatments for chronic pain sufferers. Early development centered on the Axium Neurostimulator System, which gained pivotal traction through clinical trials and regulatory progress, culminating in landmark U.S. pivotal trial enrollment completion. The partnership and investment by St. Jude Medical marked a critical milestone, enabling broader commercialization and international market access[4][5][6].
Spinal Modulation operates within the rapidly evolving field of spinal cord stimulation and neuromodulation, a sector experiencing significant technological innovation and clinical validation. The timing is favorable due to increasing recognition of neuromodulation as a superior alternative to pharmacological pain management, especially amid the opioid crisis. Market forces such as rising chronic pain prevalence, regulatory approvals, and advances in implantable device technology support growth. By introducing a novel targeted neurostimulator, Spinal Modulation influences the ecosystem by pushing the boundaries of precision therapy, encouraging further innovation and adoption of implantable pain management solutions[3][7].
Looking ahead, Spinal Modulation is poised to expand its market footprint through commercialization of the Axium System, leveraging St. Jude Medical’s distribution capabilities. Future trends shaping its journey include advancements in device miniaturization, wireless technology, and personalized neuromodulation protocols. The company’s influence may grow as it contributes to shifting pain management paradigms away from drugs toward implantable, device-based therapies. Continued clinical validation and regulatory approvals will be critical to sustaining momentum and broadening patient access, potentially positioning Spinal Modulation as a key player in the neuromodulation landscape. This trajectory ties back to its core mission of innovating to alleviate chronic pain through targeted, effective technology[1][5][6][3].
Spinal Modulation has raised $57.0M in total across 2 funding rounds.
Spinal Modulation's investors include Johnson & Johnson Innovation.
Spinal Modulation has raised $57.0M across 2 funding rounds. Most recently, it raised $30.0M Series D in June 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2011 | $30.0M Series D | Johnson & Johnson Innovation | |
| Nov 1, 2009 | $27.0M Series C | Johnson & Johnson Innovation |